Literature DB >> 29167828

The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?

Roman Groisberg1, Vivek Subbiah1.   

Abstract

Entities:  

Year:  2017        PMID： 29167828      PMCID： PMC5676203          DOI： 10.21037/tgh.2017.09.10

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  9 in total

Review 1.  The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.

Authors:  Sosipatros A Boikos; Constantine A Stratakis
Journal:  Endocrine       Date:  2014-07-16       Impact factor: 3.633

2.  Biomarker based clinical trial design.

Authors:  Richard Simon
Journal:  Chin Clin Oncol       Date:  2014-09

3.  BLU-285, DCC-2618 Show Activity against GIST.

Authors: 
Journal:  Cancer Discov       Date:  2017-01-11       Impact factor: 39.397

Review 4.  KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

Authors:  Jerzy Lasota; Markku Miettinen
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

5.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

6.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

7.  Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.

Authors:  Helen Künstlinger; Sebastian Huss; Sabine Merkelbach-Bruse; Elke Binot; Michaela Angelika Kleine; Heike Loeser; Jens Mittler; Wolfgang Hartmann; Peter Hohenberger; Peter Reichardt; Reinhard Büttner; Eva Wardelmann; Hans-Ulrich Schildhaus
Journal:  Am J Surg Pathol       Date:  2013-11       Impact factor: 6.394

8.  Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Jörg T Hartmann; Daniel Pink; Giuliano Ramadori; Peter Hohenberger; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Bengt Nilsson; Harri Sihto; Petri Bono; Raija Kallio; Jouni Junnila; Thor Alvegård; Peter Reichardt
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

9.  Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

Authors:  Heikki Joensuu; Eva Wardelmann; Harri Sihto; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Jörg T Hartmann; Daniel Pink; Silke Cameron; Peter Hohenberger; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Bengt Nilsson; Raija Kallio; Jouni Junnila; Aki Vehtari; Peter Reichardt
Journal:  JAMA Oncol       Date:  2017-05-01       Impact factor: 31.777
  9 in total
  1 in total

Review 1.  Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Trends Cancer       Date:  2018-01-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.